EpilepsyGTx
London, England, United Kingdom · Biotechnology, Health Care, Therapeutics · 2 employees
EpilepsyGTx is a late preclinical-stage biotech developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE).
Funding history
- Series A — $33.0M — Dec 2025
- Seed — $10.0M — Jun 2024
Recent signals
- Jul 22, 2026: EpilepsyGTx Appoints Dr Teresa Nunes as Chief Medical Officer
- Jul 14, 2026: EpilepsyGTx partners with ClearPoint Neuro for targeted delivery of gene therapy in epilepsy.
- Dec 10, 2025: Raised $33.0M in Series A
- Jun 24, 2024: Raised $10.0M in Seed
See plans & pricing → Track EpilepsyGTx’s funding, hiring, and signals — with verified contacts — on Fundz.